Instant detection of early signs of diabetic retinopathy using artificial intelligence (AI)

Key features

  • Screening software with AI provided by Thirona RetCAD
  • Efficient screening for diabetic retinopathy enables early intervention
  • AI automatically detects early signs of disease and classifies the results according to severity
  • The unique confocal technology of the iCare DRSplus fundus imaging system enables screening of all patients, also those with ocular media opacities
  • Swift, intuitive, and fully automated operations, and images successful on the first take
  • Screening for other eye pathologies in the future

Fast and effortless screening for diabetic patients in all care settings using artificial intelligence

iCare ILLUME is a unique combination of specialized screening software with AI and TrueColor Confocal fundus imaging. Key advantages include a fully automated workflow, high-quality detailed images without dilation, and the future option to share referrals also outside of the source organization.

Reliable and efficient review of the images by AI saves valuable time, enables early intervention and helps to increase the regional screening coverage. For the first time, screening is possible for all patients, including those with ocular media opacities such as cataract and vitreous cloudiness.

Swift, fully automated operations



The iCare DRSplus fundus imaging system is intuitive and requires minimal staff training.

High-quality images are automatically and securely stored and forwarded for processing by AI.

The report is instantly available and can be discussed with the patient during the same visit.

AI instantly detects early signs of retinal pathology

Artificial intelligence provides efficient processing for higher throughput and reliable results that match the level of a professional human grader. AI detects early signs instantly and classifies the results according to severity based on ICDR classification. This allows ophthalmologists to focus on patients who are most in need of specialized care.

Download the report

Fully automated operations offer significant timesaving

iCare ILLUME saves time and speeds up your workflow, thanks to a fully automated process. The iCare DRSplus fundus imaging system is intuitive, easy to use, and requires minimal staff training. There is no need for dilation, as DRSplus can take images through pupils down to a width of 2,5mm. After imaging, the report is instantly available for viewing and discussion with the patient.

iCare DRSplus product page

Enabling digital screening pathways and ensuring data security and privacy

With the iCare ILLUME Connect referrals can also be shared outside your organization to increase patient care compliance. At iCare, data security and privacy meet the highest standards. Screening results can be stored in most widely used electronic health record systems. This improves communication between caregivers.

Read more!

iCare ILLUME offers versatile business benefits

In primary care, efficient screening helps to manage the eye health of the diabetic patient population, use scarce resources wisely, and save considerable costs through early intervention. With iCare ILLUME, practice owners can offer screening as a new service, giving customers another reason to visit the practice and complementing the practice’s comprehensive approach to eye health.

High-quality images meet the requirements of AI on the first take

Excellent image quality is the prerequisite for reliable and efficient screening. iCare’s TrueColor Confocal Technology presents accurate documentation of the retina in detail-rich images which seldom need to be retaken for analysis by AI. iCare DRSplus can also capture high-quality images through ocular media opacities (cataract, vitreous) – enabling the screening of diabetic retinopathy suspects already suffering from these.

PLEASE NOTE: Not all products, services or offers referenced are approved or offered in every market, and approved labelling and instructions may vary from one country to another. Product specifications are subject to change in design and scope of delivery and as a result of ongoing technical developments.